{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:22:16Z","timestamp":1788632536793,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0073\/2023\/RIA2"],"award-info":[{"award-number":["0073\/2023\/RIA2"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004733","name":"Universidade de Macau","doi-asserted-by":"publisher","award":["MYRG-GRG2023-00048-ICMS"],"award-info":[{"award-number":["MYRG-GRG2023-00048-ICMS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015249","name":"University of Macau State Key Laboratory of Quality Research in Chinese Medicine","doi-asserted-by":"publisher","award":["005\/2023\/SKL"],"award-info":[{"award-number":["005\/2023\/SKL"]}],"id":[{"id":"10.13039\/501100015249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.biopha.2024.117503","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T06:27:24Z","timestamp":1727764044000},"page":"117503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Aspirin reduces Ponatinib-induced cardiovascular toxic phenotypes and death in zebrafish"],"prefix":"10.1016","volume":"180","author":[{"given":"Ruiqi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheong-Meng","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2024.117503_bib1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.117503_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.biopha.2024.117503_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2013.12.007","article-title":"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA","volume":"42","author":"Sadovnik","year":"2014","journal-title":"Exp. Hematol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117503_bib4","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3892\/or.2013.2386","article-title":"Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1","volume":"29","author":"Ren","year":"2013","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2024.117503_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2141.2012.09085.x","article-title":"Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation","volume":"157","author":"Zirm","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117503_bib6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","article-title":"Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies","volume":"10","author":"Gozgit","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117503_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","article-title":"The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear","volume":"135","author":"Loren","year":"2015","journal-title":"Thromb. Res"},{"key":"10.1016\/j.biopha.2024.117503_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.biopha.2024.117503_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1634\/theoncologist.2015-0253","article-title":"Ponatinib: accelerated disapproval","volume":"20","author":"Gainor","year":"2015","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.biopha.2024.117503_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2024.117503_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/sj.clpt.6100223","article-title":"Zebrafish: An emerging model system for human disease and drug discovery","volume":"82","author":"Kari","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2024.117503_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0498-345","article-title":"Vertebrate genome evolution and the zebrafish gene map","volume":"18","author":"Postlethwait","year":"1998","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.biopha.2024.117503_bib13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/bies.10326","article-title":"Zebrafish: a new model on the pharmaceutical catwalk","volume":"25","author":"Langheinrich","year":"2003","journal-title":"Bioessays"},{"issue":"10","key":"10.1016\/j.biopha.2024.117503_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd4627","article-title":"Zebrafish as tools for drug discovery","volume":"14","author":"MacRae","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9-10","key":"10.1016\/j.biopha.2024.117503_bib15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.drudis.2008.03.002","article-title":"Zebrafish: a predictive model for assessing drug-induced toxicity","volume":"13","author":"McGrath","year":"2008","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.biopha.2024.117503_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13578-022-00838-y","article-title":"Neuropathy-associated Fars2 deficiency affects neuronal development and potentiates neuronal apoptosis by impairing mitochondrial function","volume":"12","author":"Chen","year":"2022","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117503_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13578-023-01064-w","article-title":"Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma","volume":"13","author":"De Paolo","year":"2023","journal-title":"Cell Biosci."},{"key":"10.1016\/j.biopha.2024.117503_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.freeradbiomed.2023.08.021","article-title":"Azoramide prevents MPP(+)-induced dopaminergic neuronal death via upregulating ER chaperone BiP expression","volume":"208","author":"Ai","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"62","key":"10.1016\/j.biopha.2024.117503_bib19","doi-asserted-by":"crossref","first-page":"31958","DOI":"10.18632\/oncotarget.24110","article-title":"Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway","volume":"9","author":"Ai","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.biopha.2024.117503_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/MOH.0000000000000075","article-title":"Zebrafish as a model system for the study of hemostasis and thrombosis","volume":"21","author":"Weyand","year":"2014","journal-title":"Curr. Opin. Hematol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117503_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/zeb.2016.1263","article-title":"A Zebrafish thrombosis model for assessing antithrombotic drugs","volume":"13","author":"Zhu","year":"2016","journal-title":"Zebrafish"},{"issue":"1","key":"10.1016\/j.biopha.2024.117503_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12012-015-9315-1","article-title":"FGF2 prevents sunitinib-induced cardiotoxicity in zebrafish and cardiomyoblast H9c2 cells","volume":"16","author":"Cui","year":"2016","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.biopha.2024.117503_bib23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.chemosphere.2017.04.090","article-title":"In vivo cardiovascular toxicity induced by acetochlor in zebrafish larvae","volume":"181","author":"Liu","year":"2017","journal-title":"Chemosphere"},{"key":"10.1016\/j.biopha.2024.117503_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173292","article-title":"Ponatinib-induced ischemic stroke in larval zebrafish for drug screening","volume":"889","author":"Zhu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117503_bib25","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/cvr\/cvz006","article-title":"Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies","volume":"115","author":"Singh","year":"2019","journal-title":"Cardiovasc Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.117503_bib26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117503_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020062","article-title":"Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse","volume":"6","author":"Armstrong","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2024.117503_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060943","article-title":"Calcium channels in the heart: disease states and drugs","volume":"11","author":"Shah","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.biopha.2024.117503_bib29","doi-asserted-by":"crossref","first-page":"a006684","DOI":"10.1101\/cshperspect.a006684","article-title":"Vascular development in the zebrafish","volume":"2","author":"Gore","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"11","key":"10.1016\/j.biopha.2024.117503_bib30","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/dvdy.24497","article-title":"Heart function and hemodynamic analysis for zebrafish embryos","volume":"246","author":"Yalcin","year":"2017","journal-title":"Dev. Dyn."},{"issue":"3","key":"10.1016\/j.biopha.2024.117503_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12030693","article-title":"Zebrafish as a model for cardiovascular and metabolic disease: the future of precision medicine","volume":"12","author":"Angom","year":"2024","journal-title":"Biomedicines"},{"issue":"15","key":"10.1016\/j.biopha.2024.117503_bib32","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/bloodadvances.2019000034","article-title":"Ponatinib treatment promotes arterial thrombosis and hyperactive platelets","volume":"3","author":"Merkulova","year":"2019","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.biopha.2024.117503_bib33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.biopha.2024.117503_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294438","article-title":"Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2024.117503_bib35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117503_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/5584_2016_123","article-title":"Role of P2Y(12) receptor in thrombosis","volume":"906","author":"Zhang","year":"2017","journal-title":"Adv. Exp. Med Biol."},{"issue":"Suppl 1(Suppl 1","key":"10.1016\/j.biopha.2024.117503_bib37","article-title":"Antiplatelet drugs","volume":"147","author":"Born","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117503_bib38","doi-asserted-by":"crossref","first-page":"H3636","DOI":"10.1152\/ajpheart.01105.2006","article-title":"Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction","volume":"293","author":"Tailor","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117503_bib39","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/mco2.363","article-title":"Arachidonic acid metabolism in health and disease","volume":"4","author":"Zhang","year":"2023","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.biopha.2024.117503_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbrc.2006.11.007","article-title":"The zebrafish genome contains two inducible, functional cyclooxygenase-2 genes","volume":"352","author":"Ishikawa","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2024.117503_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285216","article-title":"Preventive effect and mechanism of Tibetan tea extract on thrombosis in arachidonic acid-induced zebrafish determined via RNA-seq transcriptome profiles","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"issue":"41","key":"10.1016\/j.biopha.2024.117503_bib42","doi-asserted-by":"crossref","first-page":"12970","DOI":"10.1523\/JNEUROSCI.2373-09.2009","article-title":"Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli","volume":"29","author":"Garcia-Bueno","year":"2009","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.biopha.2024.117503_bib43","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2024.117503_bib44","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"I. Investigators, long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.117503_bib45","first-page":"2013","article-title":"The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells","volume":"7","author":"Zhang","year":"2014","journal-title":"Onco Targets Ther."},{"issue":"2","key":"10.1016\/j.biopha.2024.117503_bib46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.117.246116","article-title":"Pharmacokinetic assessment of cooperative efflux of the multitargeted kinase inhibitor ponatinib across the blood-brain barrier","volume":"365","author":"Laramy","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.117503_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030383","article-title":"A new algorithm integrating molecular response, toxicity, and plasma level measures for ponatinib dose choice in patients affected by chronic myeloid leukemia","volume":"16","author":"Galimberti","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2024.117503_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.642005","article-title":"Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase","volume":"11","author":"Castagnetti","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117503_bib49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000504664","article-title":"Management of ponatinib in patients with chronic myeloid leukemia with cardiovascular risk factors","volume":"64","author":"Santoro","year":"2019","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.biopha.2024.117503_bib50","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s12276-023-01002-3","article-title":"Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction","volume":"55","author":"Kim","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.117503_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005783","article-title":"Glycine and folate ameliorate models of congenital sideroblastic anemia","volume":"12","author":"Fernandez-Murray","year":"2016","journal-title":"PLoS Genet"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224013891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224013891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:52:37Z","timestamp":1773967957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224013891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":51,"alternative-id":["S0753332224013891"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117503","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin reduces Ponatinib-induced cardiovascular toxic phenotypes and death in zebrafish","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117503"}}